1. Efficacy and Safety of Garadacimab in Combination with Standard of Care Treatment in Patients with Severe COVID-19
- Author
-
Papi, Alberto, Stapleton, Renee D., Shore, Paul M., Bica, Mihai Alexandru, Chen, Younan, Larbig, Michael, and Welte, Tobias
- Subjects
United States. National Institute of Allergy and Infectious Diseases -- Standards ,Blood -- Medical examination ,Medical research ,Medicine, Experimental ,Mortality ,Anticoagulants (Medicine) -- Complications and side effects ,Immunoglobulin G ,Monoclonal antibodies -- Complications and side effects ,Kallikrein ,Health - Abstract
Background Garadacimab, a fully human IgG4 monoclonal antibody, inhibits the kallikrein-kinin pathway at a key initiator, activated coagulation factor XII (FXIIa), and may play a protective role in preventing the progression of COVID-19. This phase 2 study evaluated the efficacy and safety of garadacimab plus standard of care (SOC) versus placebo plus SOC in patients with severe COVID-19. Methods Patients hospitalised with COVID-19 were randomised (1:1) to a single intravenous dose of garadacimab (700 mg) plus SOC or placebo plus SOC. Co-primary endpoint was incidence of endotracheal intubation or death between randomisation and Day 28. All-cause mortality, safety and pharmacokinetic/pharmacodynamic parameters were assessed. Results No difference in incidence of tracheal intubation or death (p = 0.274) or all-cause mortality was observed (p = 0.382). Garadacimab was associated with a lower incidence of treatment-emergent adverse events (60.3% vs 67.8%) and fewer serious adverse events (34 vs 45 events) versus placebo. No garadacimab-related deaths or bleeding events were reported, including in the 45.9% (n = 28/61) of patients who received concomitant heparin. Prolonged activated partial thromboplastin time (aPTT), and increased coagulation factor XII (FXII) levels were observed with garadacimab versus placebo to Day 14, whilst FXIIa-mediated kallikrein activity (FXIIa-mKA) was suppressed to Day 28. Conclusion In patients with severe COVID-19, garadacimab did not confer a clinical benefit over placebo. Transient aPTT prolongation and suppressed FXIIa-mKA showed target engagement of garadacimab that was not associated with bleeding events even with concomitant anticoagulant use. The safety profile of garadacimab was consistent with previous studies in patients with hereditary angioedema. ClinicalTrials. gov Identifier NCT04409509. Date of registration: 28 May, 2020., Author(s): Alberto Papi [sup.1], Renee D. Stapleton [sup.2], Paul M. Shore [sup.3], Mihai Alexandru Bica [sup.4], Younan Chen [sup.5], Michael Larbig [sup.6], Tobias Welte [sup.7] Author Affiliations: (1) grid.8484.0, 0000 [...]
- Published
- 2023
- Full Text
- View/download PDF